HHS awarded Moderna $73M for Zika vaccine R&D, a significant investment in biodefense preparedness

Contract Overview

Contract Amount: $72,965,186 ($73.0M)

Contractor: Modernatx, Inc.

Awarding Agency: Department of Health and Human Services

Start Date: 2016-09-01

End Date: 2024-07-01

Contract Duration: 2,860 days

Daily Burn Rate: $25.5K/day

Competition Type: FULL AND OPEN COMPETITION

Number of Offers Received: 1

Pricing Type: COST PLUS FIXED FEE

Sector: R&D

Official Description: MODERNA THERAPEUTICS, INC:ADVANCE THE DEVELOPMENT OF AN MRNA VACCINE FOR THE PREVENTION OF ZIKA VIRUS:: IGF::OT::IGF

Place of Performance

Location: CAMBRIDGE, MIDDLESEX County, MASSACHUSETTS, 02139

State: Massachusetts Government Spending

Plain-Language Summary

Department of Health and Human Services obligated $73.0 million to MODERNATX, INC. for work described as: MODERNA THERAPEUTICS, INC:ADVANCE THE DEVELOPMENT OF AN MRNA VACCINE FOR THE PREVENTION OF ZIKA VIRUS:: IGF::OT::IGF Key points: 1. The contract's cost-plus-fixed-fee structure incentivizes efficient research while allowing for flexibility in development. 2. Full and open competition suggests a robust market for vaccine development services, potentially leading to competitive pricing. 3. The contract duration of nearly 8 years indicates a long-term commitment to developing a critical public health countermeasure. 4. While the specific performance metrics are not detailed, the focus on R&D implies a high degree of technical risk. 5. This award positions Moderna as a key player in the government's efforts to combat emerging infectious diseases. 6. The contract's value, while substantial, should be viewed in the context of the high costs associated with novel vaccine development.

Value Assessment

Rating: good

The $73 million award to Moderna for Zika vaccine development appears reasonable given the scope and duration of the research. Comparing this to other government contracts for novel vaccine development, which often run into hundreds of millions of dollars over many years, suggests a potentially good value. The cost-plus-fixed-fee (CPFF) pricing structure, while not always the most cost-effective, allows for the necessary flexibility and risk-sharing inherent in early-stage R&D. Benchmarking against similar biotechnology R&D efforts would provide further insight, but the initial award seems aligned with industry norms for this type of advanced research.

Cost Per Unit: N/A

Competition Analysis

Competition Level: full-and-open

The contract was awarded under full and open competition, indicating that multiple qualified vendors had the opportunity to bid. This process is designed to foster a competitive environment, which typically drives down prices and encourages innovation. The specific number of bidders is not provided, but the open competition suggests that the government sought the best value from the market. This approach is generally favorable for ensuring fair pricing and access to a wide range of technological capabilities.

Taxpayer Impact: Taxpayers benefit from full and open competition through potentially lower costs and access to the most innovative solutions. This process helps ensure that government funds are used efficiently by leveraging market forces to achieve the best possible outcome for public health initiatives.

Public Impact

The primary beneficiaries are the public, through the potential development of a vaccine to prevent Zika virus infection and its associated health risks. The services delivered include advanced research and development activities aimed at creating a novel mRNA vaccine. The geographic impact is global, as Zika is a widespread threat, and a successful vaccine would have international public health implications. Workforce implications include support for highly skilled scientific and technical jobs in the biotechnology sector.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

The long contract duration (nearly 8 years) could lead to cost overruns if research timelines are extended.
The CPFF contract type carries inherent risks of cost escalation if not managed closely.
The success of novel vaccine development is inherently uncertain, posing a risk to the investment.
Dependence on a single contractor for a critical countermeasure could pose supply chain risks if not diversified.

Positive Signals

Awarding to Moderna, a leader in mRNA technology, leverages proven expertise for a critical health threat.
Full and open competition suggests a healthy market and potential for competitive pricing and innovation.
The significant investment signals a strong commitment to addressing the Zika virus threat.
The long-term nature of the contract allows for sustained focus and development of a complex product.

Sector Analysis

The biotechnology and pharmaceutical sector is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Government contracts play a crucial role in funding early-stage research and development for public health threats, often de-risking novel technologies for commercialization. Spending in this area is driven by emerging diseases, national security concerns, and the need for advanced medical countermeasures. Comparable spending benchmarks for vaccine development can vary widely, but investments in the tens to hundreds of millions of dollars are common for novel vaccine candidates.

Small Business Impact

This contract does not appear to have a specific small business set-aside. However, the nature of advanced biotechnology R&D often involves large prime contractors who may then subcontract with smaller, specialized firms. It is important to assess whether subcontracting opportunities are being made available to small businesses to ensure broad economic participation and foster innovation within the small business ecosystem.

Oversight & Accountability

Oversight for this contract is likely managed by the Department of Health and Human Services (HHS), specifically the Office of Assistant Secretary for Preparedness and Response (ASPR). Mechanisms would include regular progress reports, financial reviews, and milestone assessments. Transparency is typically maintained through contract award databases and public reporting on program achievements. Inspector General jurisdiction would apply to ensure the proper use of federal funds and prevent fraud, waste, and abuse.

Related Government Programs

Biotechnology Research and Development
Vaccine Development Programs
Emerging Infectious Disease Countermeasures
National Biodefense Strategy
mRNA Technology Platforms

Risk Flags

Long contract duration may increase risk of cost overruns.
CPFF contract type requires diligent cost oversight.
Novel vaccine development carries inherent scientific uncertainty.
Potential for scope creep in R&D projects.

Frequently Asked Questions

What is this federal contract paying for?

Department of Health and Human Services awarded $73.0 million to MODERNATX, INC.. MODERNA THERAPEUTICS, INC:ADVANCE THE DEVELOPMENT OF AN MRNA VACCINE FOR THE PREVENTION OF ZIKA VIRUS:: IGF::OT::IGF

Who is the contractor on this award?

The obligated recipient is MODERNATX, INC..

Which agency awarded this contract?

Awarding agency: Department of Health and Human Services (Office of Assistant Secretary for Preparedness and Response).

What is the total obligated amount?

The obligated amount is $73.0 million.

What is the period of performance?

Start: 2016-09-01. End: 2024-07-01.

What is Moderna's track record with government contracts, particularly in vaccine development?

Moderna has a significant track record with government contracts, especially following its prominent role in developing mRNA COVID-19 vaccines. Prior to and during the COVID-19 pandemic, the company received substantial funding from agencies like the National Institutes of Health (NIH) and the Biomedical Advanced Research and Development Authority (BARDA) for various vaccine candidates, including those targeting influenza and other infectious diseases. Their experience extends to navigating the complexities of government contracting, including regulatory compliance, reporting requirements, and milestone-based payments. This Zika vaccine contract builds upon that established relationship and demonstrated capability in developing and scaling mRNA-based therapeutics and vaccines.

How does the $73 million award compare to other government investments in Zika preparedness or vaccine R&D?

The $73 million award to Moderna for Zika vaccine development is a substantial investment, reflecting the perceived threat of the virus and the commitment to developing countermeasures. Compared to other government investments in vaccine R&D, this figure is in line with early to mid-stage development contracts for novel vaccines. For instance, government funding for COVID-19 vaccine development often reached hundreds of millions of dollars per candidate, reflecting the urgency and scale of that pandemic. Investments in preparedness for other emerging infectious diseases also typically involve multi-year, multi-million dollar contracts to advance promising technologies. This award signifies a significant, but not unprecedented, level of funding for a critical public health priority.

What are the primary risks associated with this specific contract and the development of an mRNA Zika vaccine?

The primary risks associated with this contract are multifaceted. Firstly, the inherent scientific risk in developing a novel vaccine, particularly an mRNA vaccine for a less-studied virus like Zika, is significant. There's no guarantee of efficacy or safety. Secondly, the long contract duration (nearly 8 years) introduces programmatic risks, including potential cost overruns, shifts in research priorities, or unforeseen technical challenges. The Cost Plus Fixed Fee (CPFF) contract type, while flexible, can lead to cost escalation if not meticulously managed. Finally, market and public health risks exist; if the perceived threat of Zika diminishes or alternative prevention methods emerge, the demand for this specific vaccine could decrease, impacting its ultimate utility and return on investment.

What does the 'Research and Development in Biotechnology' NAICS code indicate about the nature of the work?

The North American Industry Classification System (NAICS) code 541711, 'Research and Development in Biotechnology,' indicates that the primary focus of this contract is on scientific research and experimental development in biotechnology. This involves systematic study to gain new knowledge, with the ultimate goal of developing or improving products, processes, or services. For Moderna's Zika vaccine project, this means activities such as molecular biology, genetic engineering, immunology, and preclinical testing. It signifies that the contract is not for manufacturing or distribution but for the foundational scientific work required to create a viable vaccine candidate, involving laboratory experiments, data analysis, and iterative refinement of the vaccine's design.

How does the contract type (Cost Plus Fixed Fee) influence the government's financial exposure and the contractor's incentives?

The Cost Plus Fixed Fee (CPFF) contract type means the government agrees to pay the contractor's actual allowable costs plus a predetermined fixed fee representing profit. This structure is common in R&D where the scope of work can be uncertain and subject to change. For the government, the financial exposure is potentially high, as costs can exceed initial estimates. However, the fixed fee provides some predictability regarding profit. For the contractor (Moderna), the incentive is to perform the work efficiently to complete it within the estimated cost, as their profit (the fixed fee) remains constant regardless of the final cost. This structure balances the need for flexibility in R&D with a degree of cost control, though it requires robust government oversight to manage allowable costs effectively.

Industry Classification

NAICS: Professional, Scientific, and Technical Services › Scientific Research and Development Services › Research and Development in Biotechnology

Product/Service Code: RESEARCH AND DEVELOPMENT › N – Health R&D Services

Competition & Pricing

Extent Competed: FULL AND OPEN COMPETITION

Solicitation Procedures: NEGOTIATED PROPOSAL/QUOTE

Solicitation ID: BAA16100SOL0001

Offers Received: 1

Pricing Type: COST PLUS FIXED FEE (U)

Evaluated Preference: NONE

Contractor Details

Address: 200 TECHNOLOGY SQUARE, CAMBRIDGE, MA, 02139

Business Categories: Category Business, Corporate Entity Not Tax Exempt, Small Business, Special Designations, U.S.-Owned Business

Financial Breakdown

Contract Ceiling: $81,397,874

Exercised Options: $72,965,186

Current Obligation: $72,965,186

Actual Outlays: $23,161,344

Contract Characteristics

Commercial Item: COMMERCIAL PRODUCTS/SERVICES PROCEDURES NOT USED

Cost or Pricing Data: YES

Timeline